Tobam Boosts Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Tobam grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 30.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,808 shares of the biotechnology company's stock after purchasing an additional 8,886 shares during the quarter. Tobam's holdings in Sarepta Therapeutics were worth $2,413,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Manchester Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares during the period. Steward Partners Investment Advisory LLC lifted its position in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the period. UMB Bank n.a. grew its stake in Sarepta Therapeutics by 53.0% during the first quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock worth $51,000 after buying an additional 276 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after buying an additional 216 shares during the period. Finally, Logan Capital Management Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $61,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Analysts Set New Price Targets

SRPT has been the topic of a number of recent analyst reports. Scotiabank raised shares of Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price objective on the stock in a research note on Friday, June 6th. Bank of America reissued a "neutral" rating and set a $28.00 price target (down from $76.00) on shares of Sarepta Therapeutics in a research note on Monday. The Goldman Sachs Group reduced their target price on Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. JPMorgan Chase & Co. decreased their price objective on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating for the company in a research report on Tuesday, May 20th. Finally, Needham & Company LLC decreased their price target on Sarepta Therapeutics from $125.00 to $50.00 and set a "buy" rating for the company in a report on Monday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $99.35.

Sarepta Therapeutics Stock Down 42.1%

Shares of NASDAQ SRPT traded down $15.24 during midday trading on Monday, hitting $20.94. 42,963,556 shares of the company's stock were exchanged, compared to its average volume of 1,973,840. The firm's fifty day simple moving average is $46.25 and its 200-day simple moving average is $86.03. The company has a market cap of $2.06 billion, a PE ratio of 16.75 and a beta of 0.61. Sarepta Therapeutics, Inc. has a twelve month low of $18.33 and a twelve month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. During the same quarter in the prior year, the firm posted $0.73 EPS. Sarepta Therapeutics's quarterly revenue was up 80.2% compared to the same quarter last year. Research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.